SYRS News and Press, Syros Pharmaceuticals Inc. From 12/06/23

2023-12-06 13:46:53 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) added ~41% on Wednesday after the Massachusetts area biotech disclosed early data from a Phase 2 trial evaluating its oral leukemia drug, tamibarotene, as a combination therapy. Based on data from 19 pat...

2023-12-06 12:41:58 ET More on Mid-day movers $ stocks. Altimmune: Don't Buy The GLP-1 Move-Up Altimmune: Pemvidutide Data Reinforces Obesity Drug Outlook Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Call Transcript Altimmune weight-loss drug performed...

2023-12-06 12:33:41 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Sera Prognostics Inc (NASDAQ: SERA), MicroAlgo Inc (NASDAQ: MLGO), Kamada Ltd (NASDAQ: KMDA), Syros Pha...

2023-12-06 09:57:12 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Sera Prognostics Inc (NASDAQ: SERA), MicroAlgo Inc (NASDAQ: MLGO), ZyVersa Therapeutics Inc (NASDAQ: ZVSA), Ka...

-- 100% CR/CRi Rate in Patients Treated with Tamibarotene, Venetoclax and Azacitidine Compared to 70% in Patients Randomized to Treatment with Venetoclax and Azacitidine Alone -- -- Triplet Regimen Continues to Demonstrate Favorable Tolerability -- -- Additional Data Expecte...

2023-11-14 13:53:09 ET Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Conference Call November 14, 2023 08:30 ET Company Participants Karen Hunady - Director of Investor Relations & Corporate Communications Nancy Simonian - President & Chief Executive Of...

2023-11-14 07:32:07 ET More on Syros Pharmaceuticals Syros Pharmaceuticals Q3 2023 Earnings Preview Syros Pharmaceuticals announces job cuts, CEO change Seeking Alpha’s Quant Rating on Syros Pharmaceuticals Historical earnings data for Syros Pharmaceut...

– On track to report initial data from approximately 20 patients in SELECT-AML-1 trial in early December 2023 – – Expect to report pivotal CR data from SELECT-MDS-1 by mid-4Q 2024 – – Founding CEO, Nancy Simonian, M.D. to retire a...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Syros Pharmaceuticals Inc. (SYRS) is expected to report $-1.12 for Q3 2023